Europe's Alzheimer's experts unconvinced by new drug

Alzheimer’s disease experts in Europe, weighing the potential use of a new drug from Eisai and Biogenm say its ability to slow cognitive decline may not outweigh its health risk, or be worth the toll on scarce healthcare resources.